UK‑based Genomics Ltd. launched Mystra, an AI‑enabled genomics platform designed to accelerate target and biomarker discovery by integrating roughly 20,000 GWAS datasets. The company said Mystra automates evidence aggregation and scoring to help drug developers prioritize targets and indications quickly, and will be showcased at ASHG where users can trial the portal. Genomics positions Mystra as a way to democratize complex genetic evidence synthesis with machine‑learning pipelines and scalable cloud access. The platform offers self‑service and enterprise engagement models and emphasizes rapid hypothesis generation for translational teams. If Mystra meets performance claims on reproducibility and interpretability, it could shorten target validation timelines and reduce costly late‑stage failures — though adoption will hinge on independent benchmarking against existing genetic and multiomic resources.